Verrica Pharmaceuticals Inc. VRCA
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology drug developer. Its lead program, YCANTH (VP-102, cantharidin), is in Phase 3 for Molluscum contagiosum. Its next catalyst on record is YCANTH (common warts): Phase 3 top-line data (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: YCANTH (common warts) — Phase 3 top-line data (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| YCANTH (VP-102) | Molluscum contagiosum | device-combination | Approved |
| VP-102 (COVE-2, COVE-3, COVE-4) | Common warts | device-combination | Phase 3 |
| VP-315 | Basal cell carcinoma | biologic-other | Phase 2 |
Recent results and decisions
- Jun 22, 2026started First U.S. patient dosed June 22, 2026 in second Phase 3 trial (COVE-3) of YCANTH in common warts.
On June 22, 2026, the Company announced that the first U.S. patient was dosed in the second pivotal clinical trial (COVE-3) in its global Phase 3 program evaluating YCANTH® (VP-102) for the treatment of common warts in the US and Japan.
Filing - Mar 11, 2026positive New abscopal analysis: 3 of 14 observed-but-untreated lesions had complete histologic clearance and tumor size fell 67% across all 14.
Specifically, 3 out of the 14 lesions had complete histologic clearance and there was a 67% overall reduction in tumor size across all 14 lesions.
Filing - Dec 1, 2025started First patient dosed in December 2025 in first Phase 3 trial (COVE-2) of YCANTH in common warts.
On January 7, 2026, the Company announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.